Literature DB >> 22884309

Adaptive response in the antioxidant defence system in the course and outcome in first-episode schizophrenia patients: a 12-months follow-up study.

Fátima Ruiz-Litago1, Jesús Seco, Enrique Echevarría, Mónica Martínez-Cengotitabengoa, Javier Gil, Jon Irazusta, Ana María González-Pinto.   

Abstract

Correlation of plasma antioxidant enzyme activity with the course and outcome in first-episode schizophrenia patients (n=49) was analyzed in order to assess the possible utility of peripheral markers of oxidative stress as prognostic factors. These markers were measured shortly after the onset of schizophrenia, and again 1, 6 and 12 months later. A decrease in catalase (CAT), glutathione peroxidase (GPx), superoxide dismutase (SOD), and glutathione (GSH) levels and total antioxidant status (TAS), as well as an increase in thiobarbituric acid reactive substances (TBARS), were observed 1 month after (p<0.05). 6-Months later, there was a reduction in TAS, GSH, SOD and GPx, and a increase in TBARS (p<0.05), with a normalization of CAT levels, indicating a persistent alteration of the antioxidant system and the maintenance of oxidative stress. At 12-months, a considerable decrease was observed in TBARS. Additionally, while the level of GPx decreased (p<0.05) further, SOD and GSH levels and TAS were normalizing, indicating a partial regeneration of the antioxidant defence system. These results indicate the possible contribution of oxidative stress to the onset and pathophysiology of schizophrenia, suggesting the involvement of an adaptive response in the antioxidant defence system in the course and outcome in first-episode schizophrenia patients.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22884309     DOI: 10.1016/j.psychres.2012.07.024

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  8 in total

Review 1.  Biomarkers in schizophrenia: A focus on blood based diagnostics and theranostics.

Authors:  Chi-Yu Lai; Elizabeth Scarr; Madhara Udawela; Ian Everall; Wei J Chen; Brian Dean
Journal:  World J Psychiatry       Date:  2016-03-22

Review 2.  In vivo assessment of neurotransmitters and modulators with magnetic resonance spectroscopy: application to schizophrenia.

Authors:  S Andrea Wijtenburg; Shaolin Yang; Bernard A Fischer; Laura M Rowland
Journal:  Neurosci Biobehav Rev       Date:  2015-01-19       Impact factor: 8.989

3.  Resveratrol, a SIRT1 Activator, Ameliorates MK-801-Induced Cognitive and Motor Impairments in a Neonatal Rat Model of Schizophrenia.

Authors:  Juan Niu; Yuquan Cao; Yongjuan Ji
Journal:  Front Psychiatry       Date:  2020-07-24       Impact factor: 4.157

4.  Increased Markers of Oxidative Stress and Positive Correlation Low-Grade Inflammation with Positive Symptoms in the First Episode of Schizophrenia in Drug-Naïve Patients.

Authors:  Ewa Dudzińska; Kinga Szymona; Jacek Bogucki; Wojciech Koch; Ewelina Cholewińska; Robert Sitarz; Katarzyna Ognik
Journal:  J Clin Med       Date:  2022-05-02       Impact factor: 4.964

Review 5.  NOX2 As a Target for Drug Development: Indications, Possible Complications, and Progress.

Authors:  Becky A Diebold; Susan M E Smith; Yang Li; J David Lambeth
Journal:  Antioxid Redox Signal       Date:  2014-03-24       Impact factor: 8.401

6.  Extracellular free water and glutathione in first-episode psychosis-a multimodal investigation of an inflammatory model for psychosis.

Authors:  Tyler A Lesh; Richard J Maddock; Amber Howell; Huan Wang; Costin Tanase; J Daniel Ragland; Tara A Niendam; Cameron S Carter
Journal:  Mol Psychiatry       Date:  2019-05-28       Impact factor: 15.992

7.  A multimodal approach to studying the relationship between peripheral glutathione, brain glutamate, and cognition in health and in schizophrenia.

Authors:  Kun Yang; Anouk Marsman; Subechhya Pradhan; Jennifer M Coughlin; Min Wang; Rebecca E Ward; Susanne Bonekamp; Emily B Ambinder; Cecilia P Higgs; Pearl K Kim; Jamie A Edwards; Mark Varvaris; Hongxing Wang; Sotirios Posporelis; Shuangchao Ma; Tsuyoshi Tsujimura; Richard A E Edden; Martin G Pomper; Thomas W Sedlak; Margot Fournier; David J Schretlen; Nicola G Cascella; Peter B Barker; Akira Sawa
Journal:  Mol Psychiatry       Date:  2020-10-19       Impact factor: 15.992

8.  Elevated serum levels of malondialdehyde and cortisol are associated with major depressive disorder: A case-control study.

Authors:  Md Rabiul Islam; Md Reazul Islam; Imtiaz Ahmed; Abdullah Al Moktadir; Zabun Nahar; Mohammad Safiqul Islam; Shelina Fatema Binte Shahid; Sheikh Nazrul Islam; Md Saiful Islam; Abul Hasnat
Journal:  SAGE Open Med       Date:  2018-05-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.